SynthesisFrontiers in immunology2025
The impact of histone deacetylase inhibition on neurobehavioural outcomes in preclinical models of traumatic and non-traumatic spinal cord injury: a systematic review.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The impact of aging on locomotor recovery in preclinical models of traumatic spinal cord injury: a systematic review.Frontiers in neurologyPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Spinal cord injury (SCI) is a traumatic injury resulting in significant life-changing disability. Elucidating the molecular processes associated with SCI may help to design novel therapeutics targeted at improving patient outcomes. Current pharmacological candidates include histone deacetylase (HDAC) inhibitors, whose anti-inflammatory properties are postulated to be of value in SCI. The objective was to synthesise the impact of HDAC inhibitors on neurobehavioural outcomes in preclinical studies of traumatic and non-traumatic SCI and to evaluate the suitability of HDAC inhibitors for clinical trials in patients with SCI. Methods: The review was prospectively registered with PROSPERO (CRD42023477882) and conducted following PRISMA 2020 guidelines. MEDLINE and Embase were searched. Studies of animal models of traumatic or non-traumatic SCI evaluating the effect of HDAC inhibition on neurobehavioural outcomes were eligible for inclusion. Risk of bias was assessed using the SYRCLE checklist. Screening, data-extraction and risk of bias assessments were completed in duplicate. Results: Of 10,549 studies identified, 42 studies met inclusion criteria. Animal models were rats (n=28), mice (n=13) and rabbits (n=1). SCI models included spinal cord contusion (n=24), epidural compression (n=2), vascular clip compression (n=6), hemisection (n=5), ischaemia/reperfusion injury (n=4) and dorsolateral funiculus crush (n=1). Valproate was the most frequently studied HDAC inhibitor (n=20), followed by 4-phenylbutyrate (4-PBA; n=7) and RGFP966 (n=3). Trichostatin A, tubastatin A, entinostat, PCI-34051, scriptaid, CI-994, TMP269, vorinostat, 3-TYP, SW-100 and ACY1215 were each evaluated in a single study. Three studies used the sirtuin-1 (HDAC class III) inhibitor EX527 administered with an activator molecule: melatonin (n=1), MLN4924 (n=1) and oxymatrine (n=1). Locomotor function was assessed in 98% (41/42) of studies, with improvement in locomotor outcome reported in 73% (30/41). Pain and anxiety were evaluated in one study, in which significant improvement was demonstrated. Conclusion: HDAC inhibitors are associated with functional motor recovery and improved anxiety and pain scores in preclinical models of SCI. However, the results should be interpreted with caution as risk of bias of included studies was unclear. These results support further investigation of HDAC inhibitors in preclinical studies before translation into clinical trials. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023477882.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.